ImmunoCellular Therapeutics, Ltd Announces Licensing Agreement with Targepeutics, Inc. for Worldwide Intellectual Property Rights to Validated Immunotherapy Target
6/22/2010 7:48:57 AM
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular’s acquisition of Targepeutics’ worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2 (IL13Ra2). The agreement includes Targepeutics’ rights under an issued U.S. patent and under certain other issued or pending patents and applications.
comments powered by